Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Nomegestrol is a synthetic progestogen and a derivative of 19-norprogesterone. It acts as a highly selective agonist of the progesterone receptor, with minimal affinity for other steroid receptors, thereby lacking significant androgenic, estrogenic, or glucocorticoid effects. It is primarily used in hormonal contraception (often in combination with estradiol) and in hormone replacement therapy for the treatment of menopausal symptoms and gynecological disorders such as dysmenorrhea or endometriosis. Beyond its reproductive health applications, nomegestrol has been investigated for its potential neuroprotective and immunomodulatory effects in multiple sclerosis, specifically to prevent postpartum relapses, although clinical trials in this indication have not demonstrated efficacy.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on nomegestrol.